Cord blood stem cells(Tatcitus Therapeutics/Mount Sinai Health System)

N/A

Report date: 2022/03/14 17:16:59

Base Information

Drug NameCord blood stem cells(Tatcitus Therapeutics/Mount Sinai Health System)
Drug Alias Name脐带血干细胞(Tatcitus Therapeutics/Mount Sinai Health System)HSC-100
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionHematopoietic progenitor cell antigen CD34 modulatorsStem cell replacements
TargetsHematopoietic progenitor cell antigen CD34
Therapy Area/IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLymphoma, Non-Hodgkin +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIcahn School Of Medicine At Mount SinaiTatcitus Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesTacitus Therapeutics IncIcahn School Of Medicine At Mount Sinai
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLymphoma, Non-Hodgkin +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A